Table 3.
Comparison of demographic and clinical information between two sites
| SZ | HC | |||||||
|---|---|---|---|---|---|---|---|---|
| Main | Validated | t/χ2 | p | Main | Validated | t/χ2 | p | |
| Demographics | ||||||||
| Age (years) | 43.22 (10.885) | 36.50 (7.14) | 3.168 | .002 | 42.04 (12.165) | 43.22 (10.885) | −.515 | .608 |
| Gender (male%) | 41.18% | 82.35% | 14.167 | .000 | 35.29% | 44.44% | .625 | .470 |
| Education (years) | 12.07 (2.946) | 12.18 (2.208) | −.182 | .856 | 12.80 (3.731) | 12.07 (2.946) | 1.105 | .272 |
| Estimated IQ | 107.68 (14.215) | 93.94 (24.799) | 3.206 | .002 | 119.76 (11.735) | 107.68 (14.215) | 4.663 | .000 |
| Clinical characteristics | ||||||||
| Onset age (years) | 25.41 (9.185) | 24.17 (6.644) | .594 | .554 | ||||
| Course (years) | 16.66 (8.067) | 10.54 (7.868) | 3.070 | .003 | ||||
| PANSS total | 51.69 (14.771) | 67.72 (12.378) | −4.678 | .000 | ||||
| PANSS positive | 11.63 (4.858) | 10.00 (3.873) | 1.461 | .148 | ||||
| PANSS negative | 13.39 (5.783) | 23.16 (3.118) | −7.884 | .000 | ||||
| PANSS general | 26.67 (7.618) | 30.84 (7.238) | −2.28 | .025 | ||||
| CPZ equivalent dose (mg) | 236.56 (172.208) | 287.05 (193.830) | −1.024 | .310 | ||||
| PANSS5 negative | 15.20 (6.636) | 28.17 (4.428) | −8.544 | .000 | ||||
| PANSS5 positive | 10.47 (4.888) | 8.17 (2.973) | 2.127 | .037 | ||||
| PANSS5 disorganized | 15.22 (4.500) | 17.09 (4.067) | −1.704 | .093 | ||||
| PANSS5 excited | 5.61 (2.155) | 5.92 (2.701) | −.533 | .596 | ||||
| PANSS5 anxiety | 8.75 (3.918) | 8.76 (3.358) | −.016 | .987 | ||||
Note. Table values: mean (SD).
Abbreviations: CPZ, chlorpromazine; HC, healthy controls; main, main data set; PANSS, the Positive and Negative Syndrome Scale; PANSS5, the symptom domains calculated by the five‐factor model; SZ, patients with schizophrenia; validated: validated data set.